Although most of these GPCR-targeted medications have been in use to treat psychiatric disorders since the 1950s (For review [26]), our understanding of their mechanisms in modulating the pathophysiology and improving the clinical symptoms remains limited and equally limited is our understanding of the roles of GPCRs in the etiology of these diseases. This evidence concerns the gene GPBAR1 and psychiatric disorder.